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The wild type cytochrome P450 monooxygenase enzyme CYP102A1 (P450Bm3) has low activity 
for cycloalkane oxidation. The oxidation of these substrates by variants of this enzyme in 
combination with a selection of perfluorinated decoy molecules (PFCs) was investigated to improve 
productivity. The use of rate accelerating variants, which have mutations located outside of the 
substrate binding pocket as well as an active site variant of CYP102A1 (A74G/F87V/L188Q) all 
enhanced cycloalkane oxidation (C5 to C10). The addition of the decoy molecules to the WT and 
the rate accelerating mutants of CYP102A1 boosted the substrate oxidation rates even further. 
However, the levels of cycloalkanol product decreased with the larger alkanes when the decoy 
molecules were used with the mutant A74G/F87V/L188Q, which contained mutations within the 
substrate binding pocket. For the majority of the enzymes and PFC decoy molecule combinations 
the highest levels of oxidation were obtained with cyclooctane. When larger second generation 
decoy molecules, based on modified amino acids were utilised there was a significant improvement 
in the oxidation of the smaller cycloalkanes by the WT enzyme another variant. This resulted in 
significant improvements in biocatalytic oxidation of cyclopentane and cyclohexane. However, the 
use of these optimised decoy molecules did not significantly improve cycloalkane oxidation over 
the fluorinated fatty acid derivatives when combined with the best rate accelerating variant, 
R47L/Y51F/I401P. Overall our approach enabled the cycloalkanes to be oxidised 300- to 8000-fold 
more efficiently than the WT enzyme at product formation rates in excess of 500 and up to 1700 
nmol.nmol-CYP–1.min–1. 
 





Cyclic alcohols are important building blocks for the production of valuable industrial chemicals 
such as cyclohexanol which is used in the production of Nylon-6,6 [1, 2]. The direct oxidation of 
cycloalkanes as a primary step for preparing the corresponding alcohols is therefore of significant 
interest [1]. The high stability of saturated C-H bonds in alkanes makes these compounds unreactive 
and they require forcing conditions such as high temperature and pressure, or a reactive oxidant in 
order to proceed [3, 4]. Various organic and inorganic methods have been used to facilitate the 
oxidation of cycloalkanes [5-7]; nevertheless these reactions remain challenging. The catalysts used 
in these chemical methods can be expensive, cannot be recovered or reused or proceed with low 
selectivity and the reactions often undergo further undesired oxidation. In addition these catalysts 
are often toxic and have an adverse impact on the environment [8].  
Enzymatic approaches for C-H hydroxylation have emerged as an alternative method for 
alkane and cycloalkane oxidation [8-13]. Efficient enzyme biocatalysis for these processes would 
benefit industry and the environment as they occur under mild conditions in aqueous media. Taking 
advantage of enzymes as biocatalysts could overcome many of the hurdles of chemocatalysts, 
namely the expense, poor selectivity and environmental toxicity [13, 14]. The cytochrome P450 
heme monooxygenases, are often Nature’s enzyme of choice when selective oxidation of a complex 
substrate is required. They catalyse the hydroxylation of unreactive C-H bonds at ambient 
temperature and pressure using a reactive compound Ι iron-oxo species [15-24].  
The CYP102A1 enzyme (P450Bm3) has often been employed as a biocatalyst to catalyse 
hydroxylation reactions [25-29]. This enzyme was discovered in the 1970s by Fulco, it was the third 
enzyme isolated from Bacillus megaterium and as such was named Bm3 [30, 31]. CYP102A1 is one of 
the most utilised P450 enzyme systems due to its high activity, solubility and self-sufficient nature. 
The electron transferring reductase domain is fused to the haem domain and it only needs the 
cofactor nicotinamide adenine dinucleotide phosphate (NADPH) and dioxygen to function [29]. 
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Fatty acids of carbon chain length 12-15 are good substrates for this enzyme and hydroxylation of 
the acids occurred at subterminal position (1 to 3) [29, 31]. Cycloalkanes are not the natural 
substrates of CYP102A1 therefore the enzyme must be modified to find conditions under which 
their hydroxylation will occur. Enzyme engineering by altering the amino acid sequences has been 
used to exploit this enzyme for alkane oxidation [25-27]. Two broad approaches have been utilised 
to adapt CYP102A1. The first makes changes in the substrate binding pocket (rational mutagenesis) 
[29, 32, 33] and the second involves directed evolution or random mutagenesis with a suitable 
screening method [28, 34-36]. 
Another approach which has been applied to enhance CYP102A1 biocatalysis is the use of 
decoy molecules [37]. Decoy molecules are inert dummy substrates which promote the catalytic 
activity of the enzyme [38]. Perfluorocarboxylic acids (PFCs) have been used with CYP102A1 with 
promising results for small alkanes and benzene [39]. The binding of the PFCs, which resemble the 
natural fatty acid substrates, initiates conformational changes in the heme domain enhancing 
substrate hydroxylation. The PFCs leave enough space in the substrate binding pocket for an 
additional molecule to bind. The decoys also appear to compel the substrates to bind more closely 
to the heme centre and facilitate the exclusion of water molecules. This is reflected in a lower 
proportion of the reducing equivalents being channelled into uncoupling pathways and resulted in 
higher levels of hydroxylation [39]. The use of decoy molecules can be combined with mutated 
variants to oxidise unnatural substrates with high catalytic productivity [39-41]. Second generation 
decoy molecules based on PFC modified L-amino acids have recently been synthesised to further 
enhance the activity of small molecules, such as propane. These bind to CYP102A1 with higher 
affinity than the PFCs. A crystal structure of the N-perfluorododecanoyl-L-tryptophan bound 
CYP102A1 heme domain has been obtained which revealed the conformational changes that are 
induced within the enzyme (Fig. 1).[42] 
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Here we use decoy molecules in combination with the wild-type (WT) enzyme and four 
engineered variants of CYP102A1 for the hydroxylation of differently sized cycloalkanes. Three of 
the variants employed KT2 (A191T/N239H/I259V/A276T/L353I), R19 
(R47L/Y51F/H171L/Q307H/N319Y) and RP (R47L/Y51F/I401P) are rate accelerating forms of the 
enzyme, generated by random or rational mutagenesis or a combination of both [43, 44]. These 
have higher activity with non-natural substrates but maintain the selectivity of the WT enzyme [39-
41]. For example the arginine 47 and tyrosine 51 residues, which have been altered in the R19 and 
RP variants, form hydrophilic interactions with fatty acid substrates and the changes render the 
active site more hydrophobic [28]. This would be expected to favour the oxidation of cycloalkanes 
but could reduce the effectiveness of the acid derived decoy molecules [28, 43]. The fourth variant 
GVQ (A74G/F87V/L188Q) was obtained from site saturation mutagenesis of three residues located 
in the active site or substrate access channel of CYP102A1 [25, 45, 46]. This variant increased the 
activity of the enzyme for hydrophobic substrates but can change the selectivity of oxidation as the 
modifications are in the active site of the enzyme [25, 47]. By using both first and second 
generation decoy molecules with different cycloalkanes we set out to gain a better understanding of 
the relationship between the size and shape of the decoy molecule and substrate to the performance 
of the enzyme catalysed oxidations. 
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2. Experimental  
2.1 General 
General reagents, organics and the PFC decoy molecules were obtained from Sigma-Aldrich, TCI, 
Fluorochem, Acros or VWR. The second generation decoy molecules, derived from amino acids 
were synthesised as described previously [42]. Buffer components, and isopropyl--D-
thiogalactopyranoside (IPTG) were from Astral Scientific (Australia). UV/Vis spectroscopy was 
performed on an Agilent Cary 60 spectrophotometer. Gas chromatography was carried out on a 
Shimadzu Tracera GC coupled to Barrier discharge Ionization Detector (BID) detector using a 
Supelcowax column (30 m × 0.32 mm × 0.25 um) and helium as the carrier gas. For cyclopentane 
and cyclohexane the oven temperature was held at 60 °C for 3 min then increased at 5 °C min-1 to 
120 °C and maintained for 2 min then increased at 25 °C min-1 to 220 °C. For cyclooctane and 
cyclodecane the oven temperature began at 100 °C for 3 min then increased at 8 °C min-1 to 220 °C 
and held at this temperature for a further 2 min. The injector and detector temperature were 250 °C 
and 270 °C respectively. Gas Chromatography-Mass Spectrometry (GC-MS) data were collected on 
a Shimadzu GC-2010 coupled to a GC-MS-QP2010S detector. Both were equipped with a DB-5 
MS fused silica column (30 m x 0.25 mm, 0.25 m). The injector and interface were maintained at 
a constant temperature of 250 °C and 280 °C. The oven temperature was held at 60 ºC for 1 min and 
then increased at 10 ºC min1 up to 200 ºC and it was maintained for 5 minutes. The product GC-
MS/GC retention times were as follows: cyclopentanol, 1.8/5.7 min; cyclohexanol 3.3/7.8 min; 
cyclooctanol 7.3/8.3 min and cyclodecanol 10.9/10.8 min. 
2.2 Protein expression and purification 
Plasmids (pET28 and pET11d) containing the relevant gene were transformed into E. coli 
BL21(DE3) competent cells and grown on an LB plate containing the relevant antibiotic 
(Supplementary data) [28]. A single colony was used to inoculate 500 mL of 2xYT media 
containing trace elements solution (CaCl2, ZnSO4.7H2O, MnSO4.H2O, Na2-EDTA, FeCl3.6H2O, 
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CuSO4.5H2O, and CoCl2.6H2O) and grown at 37 °C and 110 rpm. The incubation temperature was 
lowered to 18 °C for 30 min before the addition of 0.02 % v/v benzyl alcohol and 2 % v/v ethanol. 
After a further 30 min, protein expression was induced by the addition of 0.1 mM IPTG and the 
growth was continued for 18 – 24 h. The cell pellet was then harvested by centrifugation (5000 g, 
10 min, 4 °C) and resuspended in 40 mM phosphate buffer (pH 7.4, 1 mM DTT) and lysed by 
sonication on ice (30 cycles with 20 s on, 40 s off). Cell debris was removed by centrifugation 
(37000 g, 20 min, 4 °C) and the protein containing supernatant was loaded onto a DEAE Sepharose 
column (XK50, 200 mm × 40 mm; GE Healthcare) and eluted using a linear salt gradient of 80 – 
400 mM (NH4)2SO4 in phosphate buffer. The red-coloured fractions were combined and 
concentrated by centrifugation (1900 g, 4 °C) using ultrafiltration (30 kDa membrane, Vivacell 100, 
Sartorius). The protein was then desalted using a Sephadex G-25 medium grain column (250 mm × 
40 mm; GE Healthcare). After desalting the protein was concentrated to approximately 10 ml by 
ultrafiltration and was loaded onto a Source-Q ion-exchange column (XK26, 80 mm × 30 mm; GE 
Healthcare) using an AKTA purifier (GE Healthcare) and eluted using a linear salt gradient of 16 × 
phosphate buffer (0 – 35 %). Fractions giving an A419/A280 > 0.5 were combined and concentrated 
by ultrafiltration. An equivalent volume of 80 % glycerol was added before the protein was filter-
sterilised and stored at -20 °C. 
2.3 Substrate turnover assays 
NADPH turnover assays (final volume 1200 μL) were performed at 30 °C in Tris buffer (pH 7.4, 50 
mM). The buffer was oxygenated before the addition of the other components, including 0.2 μM 
enzyme and 120 μg bovine liver catalase. Assays were sustained at 30 °C for 1 min prior to the 
addition of the decoy molecule (100 µM) and the substrate (1 mM) followed by NADPH (from a 20 
mg mL–1 stock, to a final concentration of ~320 μM; equivalent to 2 AU). A period of 10 s was 
allowed to elapse after cofactor addition before quantitating the NADPH oxidation rate by 
monitoring the decrease in the absorbance at 340 nm. The reactions were allowed to run until all the 
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reducing equivalents were consumed. The NADPH turnover rate was derived using ε340 = 6.22 
mM−1 cm−1.  
2.4 Extraction and GC analysis 
Before extraction 200 μM of a p-cresol internal standard (10 μl of a 20 mM stock solution) was 
added, to 990 μL of the turnover. This mixture was then extracted with 400 μL ethyl acetate and the 
layers separated via centrifugation at 12000 g for 3 min. The extract was analysed by GC and a 
calibration curve was obtained in order to quantify the amount of product in each reaction. All the 
products were identified by coelution with authentic standards and MS analysis. The fatty acids 
turnovers were extracted, derivatsed and analysed by GC-MS as described previously [48]. 
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3. Results and Discussion 
3.1 Cycloalkane oxidation by CYP102A1 variants 
The heme domain in CYP102A1 is a funnel shaped shaft surrounded by hydrophobic residues e.g. 
Phe-42, Phe-87, Leu-181 and Leu-437 and is suited to the oxidation of medium to long chain fatty 
acids (Fig. 1). The WT enzyme was able to oxidise all the tested cycloalkane substrates, 
cyclopentane through to cyclodecane (Fig. 2 and Table 1). In all instances a single product arising 
from hydroxylation was observed (Scheme 1). However, the amount of product and the rate it was 
generated at was very low with the maximum activity observed for cyclooctane oxidation; 2.9 ± 0.7 
nmol.nmol-CYP–1.min–1 (henceforth abbreviated to min–1). All four of the CYP102A1 variants 
tested resulted in increased levels of oxidation product across the cycloalkanes. For all the 
cycloalkanes the RP variant resulted in the highest product formation rate. The trends in the 
remaining mutants did show variation depending on the substrate (Table 1). For example the GVQ 
variant, which should increase the size of the substrate binding pocket was an improved biocatalyst 
for cyclodecane oxidation compared to R19 and KT2 (Table 1). However, the R19 mutant was 
better at oxidising both cyclooctane and cyclohexane than GVQ (Table 1).  
The size of the cycloalkane substrate had a significant effect on the rate of product 
formation. The highest turnover rate, up to 1050 min-1, observed for all the variants, including 
GVQ, was with cyclooctane (Table 1). The maximum activity for both cyclohexane and 
cyclodecane being 411 and 283 min-1, respectively. The product formation rate with the smallest 
substrate cyclopentane was significantly slower, with the highest product formation rate observed 
being 62 min-1. Overall; by using a selection of CYP102A1 variants we were able to improve the 
product formation rates of cycloalkane oxidation from 160-fold for cyclodecane to 1500-fold for 
cyclohexane (Table 1). We also tested cyclododecane with our variants and decoy molecules but 
little or no oxidation metabolites were observed (data not shown). The R19 and RP variants, which 
contain the Arg47Leu and Tyr51Phe mutations, located at the entrance to the substrate access 
channel to allow easier access of hydrophobic substrates, were the most active variants (Table 1). 
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3.2 The effect of PFC decoy molecules on cycloalkane oxidation 
Next we assessed if cycloalkane oxidation could be improved using PFC based decoy molecules 
(PFC8 to PFC10) [37, 39]. The addition of PFCs enhanced the productive turnover of the WT 
enzyme with all four cycloalkanes (Fig. 2 and Table 1). In agreement with previous results, the 
greatest increases in the product formation rate for all the substrates were observed with PFC9 and 
PFC10. It is of note that the catalytic turnover with PFC10 was substantially higher than that 
achieved when using PFC9 for the smaller cycloalkanes (Table 1). The results obtained with these 
two decoy molecules and the larger cyclooctane and cyclodecane substrates were comparable 
(Table 1). The overall product formation rates obtained for the WT enzyme combined with these 
first generation decoy molecules was lower than with the mutant forms of CYP102A1, e.g. 204 
min-1 for cyclooctane oxidation by the WF/PFC10 combination versus 1050 min-1 for the RP variant 
alone (Table 1). 
 The addition of these fatty acid based PFC decoy molecules also upgraded cycloalkane 
oxidation with the KT2, R19 and the RP variants. With the R19 and RP variants the PFC10 decoy 
molecule also resulted in the highest turnover rates. The KT2/PFC9 combination was better than 
that with PFC10 for all the cycloalkanes (Fig. 3 and Table 1). This suggested that changes in the 
conformation or structure of the mutant enzymes may affect the decoy molecule/substrate 
preference and therefore the overall activity.  
The addition of the decoy molecules resulted in differing levels of enhancement with each 
CYP102A1 mutant compared to oxidation activity of the variant itself. In all instances the 
magnitude of the upturn in the product formation rates was lower than those observed with the WT 
enzyme (Table 1). Across all substrates the improvement observed with KT2 was greater than that 
of the R19 and RP variants. The latter two CYP102A1 mutants contain the RLYF double mutation 
at the entrance to the substrate access channel and also have higher innate product formation 
activities with the cycloalkanes. Despite the lower relative levels of enhancement compared to WT 
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and KT2, the combination of the decoy molecules with the R19 or RP variants resulted in the 
highest oxidation rates (Fig. 3 and Table 1). The R19/PFC10 combination generated the maximum 
rate of hydroxylation with cyclodecane and cyclohexane while the addition of PFC10 to the RP 
variant generated the highest activities with cyclopentane and cyclooctane (Fig. 3 and Table 1). 
As with the WT enzyme the majority of the CYP102A1 variant and decoy molecule 
combinations hydroxylated cyclooctane more effectively than the other cycloalkanes. Cyclopentane 
or cyclodecane oxidation occurred with the lowest efficiency depending on the combination used. 
The exception was the KT2 variant, which when coupled with certain decoy molecules, catalysed 
cyclohexane oxidation more rapidly than cyclooctane under the assay conditions (Table 1). 
Cyclopentane oxidation peaked at 200 min-1, a greater than 3000-fold improvement over the WT 
enzyme. Cyclohexane oxidation with the R19 and PFC10 decoy molecule occurred at a rate of 938 
min-1. The improvements achieved with cyclodecane and cyclooctane were more modest being, 
300-fold for (524 min-1) and 560-fold (1700 min-1), respectively. Importantly, for the best 
CYP102A1 variant/decoy molecule combinations the coupling efficiency, which is a measure of the 
productive use of the NADPH cofactor, was high e.g. 81 % for cyclooctane and RP/PFC10. The 
concerted effect of the CYP102A1 variants and decoy molecules resulted in a greater degree of 
enhancement with the smaller substrates which resulted in the product formation rate of 
cyclohexane (>3000-fold improvement) surpassing that of cyclodecane in their best turnovers 
(Table 1).  
3.3 The effect of PFC decoy molecules on cycloalkane oxidation by the GVQ variant 
The effect of the decoy molecules with the GVQ mutant differed from those observed with the other 
variants. The addition of all three decoy molecules resulted in a modest enhancement of 
cyclopentane oxidation, with the GVQ/PFC9 combination resulting in the highest product 
formation rate (59 ± 3.3 min-1, Table 1). Only PFC8 and PFC9 improved the catalytic performance 
of cyclohexane oxidation but in these instance the coupling efficiency of the turnover decreased 
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(Table 1). The decoy molecules diminished the amount of product generated with cyclooctane (Fig. 
3 and Fig. S1) and cyclodecane. With these larger substrates the shorter PFC8 decoy molecule had 
less of a detrimental effect on the levels of product formation (Table 1).  
The GVQ variant is the only form of CYP102A1 tested in this work which has mutations in 
the substrate binding pocket/access channel of the enzyme close to the heme. This could have a 
significant effect on how the fatty acid based decoy molecules interact and therefore bind to the 
enzyme. The Phe87 residue has been shown to have a prominent role in substrate binding in 
CYP102A1 [28, 46, 49, 50]. To assess if the GVQ variant alters the binding of the fatty acid 
molecules we investigated the oxidation of decanoic, dodecanoic and tetradecanoic acids. The GVQ 
variant altered the product distribution of dodecanoic and tetradecanoic acids compared to the WT 
enzyme (Table 1 and Fig. S2). In the GVQ variant the hydroxylation was shifted away from the -
terminus which suggested that the fatty acids were bound differently compared to the WT enzyme 
and that a greater proportion of the subterminal carbons of the fatty acid chain were located over the 
heme iron. This mutant was also able to oxidise decanoic acid whereas the WT enzyme was only 
capable of generating a trace amount of the hydroxylated metabolites (Table 1 and Fig. S2).  
These results confirm that the GVQ variant binds fatty acid like molecules in a different 
manner than the WT enzyme. Therefore one plausible explanation for the different effect of the 
decoy molecules with the GVQ variant is that the altered PFC binding orientation results in the 
decoy molecules, which contain strong unreactive C-F bonds, being positioned in between the 
cycloalkane substrate and the heme. While this enabled turnover of the P450 catalytic cycle it 
reduced productive cycloalkanol formation (Table S1). In an effort to assess if other decoy 
molecules could improve the productivity of the GVQ mutant we examined the oxidation of 
cyclooctane with PFC3 through to PFC7 as well as 4-fluoro- and pentafluorobenzoic acid (Fig. 4). 
None of these molecules stimulated the NADPH oxidation rate or the level of product formation 
above that of the GVQ variant alone (Table S1). 
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3.4 The effect of second generation decoy molecules on cycloalkane oxidation 
It is worth noting that PFC8 to PFC10 have been shown to be the optimal fatty acid derived decoy 
molecules and that shorter and longer versions, such as PFC11, reduce the activity of oxidation 
[37]. In an effort to explore how the structure of the coadditive effects the cycloalkane 
hydroxylation in more detail we utilised second generation decoy molecules which are based on 
PFCs modified with L-amino acids, PFC9-L-Ala, PFC9-L-Leu and PFC9-L-Phe (Fig. 4) [42]. The 
use of these decoys allowed CYP102A1 to catalytically hydroxylate the small gaseous alkanes 
ethane and propane [42]. When combined with the WT enzyme these second generation molecules 
also enhanced the rate of NADPH oxidation in the cycloalkane turnovers above those obtained with 
the first generation PFC decoy molecules. (Table S2). The improvements in the coupling efficiency 
and the product formation rate with the larger C8 and C10 cycloalkanes were modest (Table S2). 
However, a marked upturn in the coupling efficiency, and therefore the overall product formation 
rate, was observed with cyclopentane and cyclohexane (Fig. 5). The rate of product formation when 
the PFC9-L-Phe decoy molecule was added the WT enzyme was the greatest for both of these 
cycloalkanes (Fig. 5 and Table S2), resulting in a 21-fold improvement over the PFC10 decoy 
molecule with cyclopentane (PFR 949 ± 35 min-1) and a 5-fold enhancement with cyclohexane 
(PFR 725 ± 46 min-1). 
The second generation decoy molecules were also combined with the RP and KT2 variants 
to assess if they could enhance cycloalkane oxidation. The results were mixed with cyclohexane the 
RP/PFC9-L-Ala couple was marginally better than the R19/PFC10 combination (1010 ± 13 versus 
938 ± 20 min-1, Fig. 5, Table 1 and S2). The hydroxylation of cyclopentane with RP was also 
improved using the second generation decoys over the best fluorinated fatty acid derived molecules 
(845 ± 21 versus 501 ± 33 min-1, Table 1 and S2). Due to lower coupling efficiency, the product 
formation rate with RP/PFC9-L-Ala (845 ± 21 min-1) was lower than achieved with the WT/PFC9-
L-Phe combination (Fig. 5 and Table S2). With the RP variant and the cyclooctane and cyclodecane 
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substrates all the turnovers with the second generation decoys showed lower product formation than 
PFC10, with PFC9-L-Ala being the best. The difference between the productivity of the RP variant 
for cyclooctane and cyclodecane when partnered with the second generation decoy molecules 
compared to the smaller cycloalkanes is perhaps due to the bulkier nature of the decoy which may 
hamper access of the larger substrate in the narrow access channel of the enzyme (Fig. 1, Fig. S3 
and Table S2). The crystal structure of the heme domain of CYP102A1 with the second generation 
decoy molecule PFC9-L-Trp bound revealed that Tyr51 formed a hydrogen bond with the amide 
carbonyl group of the decoy (Fig. 1). In the RP variant Tyr51 has been mutated to a phenylalanine 
and as a result the decoy molecule may bind in a different way. Overall, PFC9-L-Ala was the best 
decoy molecule for all the cycloalkanes with RP in contrast to the WT enzyme which was better 
with PFC9-L-Phe or PFC9-L-Leu. 
When the second generation decoy molecules were used with the KT2 variant the product 
formation rate for the oxidation of the smaller cycloalkanes increased dramatically. This was 
predominantly due to superior turnover the catalytic cycle, as measured by the NADPH oxidation 
rate. The upturn for the larger substrates was not as significant. As with the WT enzyme the PFC9-
L-Phe combined with KT2 give rise to the highest product formation rates for smaller cycloalkanes 
with PFC9-L-Leu being better with the larger. The formation rate of cyclopentanol and 
cyclohexanol with PFC9-L-Phe partnered with KT2 were the highest observed in this study, with 
the smaller substrates, and were 1330 ± 68 min-1 and 1430 ± 76 min-1, respectively (Fig. 5 and Table 
S2). The combination of the second generation decoy molecules with GVQ variant also diminished 
the oxidation activity of the enzyme. (Table S1) 
Overall our results show that combining decoy molecules and CYP102A1 variant resulted in 
increased rates and efficiency of cycloalkane oxidation. The rate accelerating variants and the decoy 
molecules are both hypothesised to, and have been shown by crystal structure analysis to, enable the 
enzyme to more readily access catalytically ready conformations resulting in increased productivity. 
15 
 
They also appear to facilitate a favourable binding position for the cycloalkane substrate in relation 
to the heme which often resulted in an elevated coupling efficiency. The second generation decoy 
molecules seem to induce a greater effect on the WT and KT2 enzymes which resulted in more 
frequent turnover of the catalytic cycle. However with the RP variant these decoys were often not as 
effective as the PFC molecules or as they were with the WT and KT2 enzymes. Second generation 
decoy molecules of different size were more effective with the KT2 and WT enzymes compared to 





Cycloalkanes bear little resemblance to the fatty acid based natural substrates of CYP102A1 but the 
activity of CYP102A1 towards these unnatural substrates was enhanced by utilising rate 
accelerating variants and decoy molecules. The best variants contained the R47L/Y51F mutations at 
the entrance of substrate access channel (R19 and RP). Their combination with the first generation 
PFC10 decoy molecule provided high rates of hydroxylation. The addition of the decoy molecules 
to the R19 and RP variants had less of an impact compared to the innate product formation rate but 
still resulted in a significant enhancement in monooxygenase activity. The larger second generation 
decoy molecule PFC9-Phe boosted the productivity of the cyclopentane and cyclohexane turnovers 
of the WT enzyme and KT2 variant even further when compared to PFC10. The GVQ variant 
showed contradictory results and addition of decoy molecules reduced the level of product 
formation. This is most likely due to a different binding orientation of the PFC decoy molecule 
which hampers hydroxylation. That the highest productivity with larger substrates, such as 
cyclooctane and cyclodecane, could be achieved with the first generation decoys suggests that the 
CYP102A1 variants can accept molecules of moderate size in conjunction with the PFC molecules. 
The larger second generation decoy molecules enhanced biocatalysis with the smaller substrates to 
a significantly greater degree inferring that the active site is more restricted when these are bound to 
the enzyme. The combination of CYP102A1 variants and decoy molecules boosted the efficiency of 
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Table 1 NADPH consumption and product formation rates of cycloalkane turnovers with WT CYP102A1 and the rate accelerating variants with 
and without the presence of the first generation of decoy molecules. Coupling efficiency which is the percentage of NADPH utilised for the 
formation of cycloalkanol products are also provided. NADPH oxidation rate (NADPH) and product formation rate (PFR) are reported as mean  
S.D. (n  3) and given in nmol(nmol-CYP)–1min–1. The optimal decoy molecule has been highlighted for each enzyme/cycloalkane combination in 
bold. 
 cyclopentane cyclohexane cyclooctane cyclodecane 
NADPH coupling PFR NADPH coupling PFR NADPH coupling PFR NADPH coupling PFR 
WT 17 ± 0.7 1 ± 0 0.15 ± 0 20 ± 2 1 ± 0 0.3 ± 0.1 53 ± 3 6 ± 0 3 ± 0.2 61 ± 1 3 ± 0 1.7 ± 0.1 
WT/8 77 ± 1 2 ± 0 1.76 ± 0.1 94 ± 3 35 ± 2 33 ± 2.4 145 ± 17 63 ± 5 91 ± 4 83 ± 1 25 ± 0 20 ± 1 
WT/9 87 ± 3 5 ± 0 4 ± 0.2 175 ± 6 49 ± 2 85 ± 6 309 ± 12 64 ± 0 197 ± 7 118 ± 4 29 ± 2 34 ± 1 
WT/10 257 ± 2 13 ± 0 45 ± 1 443 ± 10 33 ± 3 144 ± 10 438 ± 23 47 ± 4 204 ± 18 249 ± 10 15 ± 1 37 ± 2 
 
R19 76 ± 4 5 ± 1 3 ± 0.1 594 ± 21 60 ± 2 355 ± 18 964 ± 7 74 ± 1 708 ± 3 196 ± 18 37 ± 2 72 ± 2 
R19/8 133 ± 6 7 ± 1 9 ± 0.9 741 ± 34 56 ± 1 416 ± 24 1170 ± 13 76 ± 3 885 ± 26 656 ± 9 41 ± 2 271 ± 20 
R19/9 205 ± 4 15 ± 0 32 ± 1.5 854 ± 43 58 ± 0 402+22 1260 ± 21 72 ± 1 906 ± 18 835 ± 24 44 ± 2 367 ± 18 
R19/10 575 ± 7 25 ± 2 142 ± 9 1620 ± 12 58 ± 1 938 ± 20 1700 ± 13 75 ± 1 1280 ± 19 1180 ± 5 44 ± 1 524 ± 9 
 
RP 352 ± 14 18 ± 0 62 ± 3 1210 ± 24 34 ± 1 411 ± 2 1570 ± 46 67 ± 1 1050 ± 16 807 ± 11 35 ± 2 283 ± 16 
RP/8 965 ± 28 37 ± 3 359 ± 17 1490 ± 6 42 ± 2 631 ± 26 2060 ± 24 74 ± 0 1530 ± 15 932 ± 18 38 ± 2 357 ± 26 
RP/9 1140 ± 43 42 ± 2 481 ± 40 1520 ±44 40 ± 0 609 ± 15 2030 ±17 75 ± 0 1520 ± 10 1100 ± 14 39 ± 1 423 ± 14 
RP/10 1180 ± 40 42 ± 1 501 ± 33 1940 ± 24 38 ± 1 741 ± 15 2100 ± 32 81 ± 2 1700 ± 25 1200 ± 26 38 ± 3 451 ± 42 
 
KT2 131 ± 8 17 ± 0 23 ± 2 244 ± 4 29 ± 1 70 ± 2.7 231 ± 6 45 ± 2 104 ± 1 116 ± 1 27 ± 1 31 ± 1 
KT2/8 341 ± 10 34 ± 0 117 ± 8 912 ± 36 52 ± 2 478 ± 27 909 ± 14 57 ± 2 518 ± 18 595 ± 21 39 ± 1 233 ± 1 
KT2/9 901 ± 16 44 ± 3 426 ± 27 1590 ± 37 45 ± 2 714 ± 54 1160 ± 20 54 ± 2 627 ± 24 1090 ± 21 28 ± 2 308 ± 15 
KT2/10 1340 ± 29 34 ± 0 397 ± 4 1960 ± 17 27 ± 3 538 ± 51 1450 ± 12 33 ± 0 473 ± 4 1740 ± 21 11 ± 0 185 ± 4 
 
GVQ 100 ± 4 4 ± 0 3.3 ± 0.1 323 ± 28 25 ± 2 81 ±  9 660 ± 22 51 ± 0 324 ± 4 1010 ± 43 24 ± 1 241 ± 8 
GVQ/8 862 ± 15 5 ± 1 40 ± 1 855 ± 21 19 ± 1 166 ± 14 988 ± 24 32 ± 2 319 ± 19 1050 ± 29 20 ± 1 208 ± 15 
GVQ/9 1490 ± 27 4 ± 3 159 ± 3 1980 ± 52 9 ± 0 183 ± 7 1310 ± 7 12 ± 0 164 ± 8 1180 ± 59 9 ± 0 110 ± 4 
GVQ/10 1530 ± 54 2 ± 1 27 ± 1 1660 ± 26 5 ± 0 75 ± 10 1760 ± 24 6 ± 1 110 ± 11 1580 ± 15 5 ± 0 72 ± 1 
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Table 2 Product distribution of fatty acids oxidation by CYP102A1 WT and GVQ variants. Very 
little product was formed with the WT and decanoic acid (Fig. S2). 
Fatty acid %Product WT GVQ 
tetradecanoic acid ω-1 48 7 
 ω-2 25 16 
 ω-3 24 31 
 ω-4 1 16 
 ω-5 0.5 25 




dodecanoic acid ω-1 37 26 
 ω-2 28 37 
 ω-3 35 34 
 ω-4 0 1 
 ω-5 0 2 
 
decanoic acid ω-1 - 55 
 ω-2 - 22 
 ω-3 - 23 
 
 





Figure 1 The crystal structure of CYP102A1 with PFC9-L-Trp decoy molecule (PDB: 3WSP), the 
access channel (grey wireframe) and hydrophobic or mutated residues (yellow) are shown. The 
hydrogen bond between PFC9-L-Trp/Y51 and PFC9-L-Trp/A74 (dashed line) and the distance 




Figure 2 GC analysis of turnovers of cyclopentane, cyclohexane, cyclooctane and cyclodecane with 
WT (solid black), WT/PFC10 (grey dash) and the optimised variant/ PFC for each substrate. The 
optimal biocatalyst combinationfor cyclopentane and cyclooctane is RP/PFC10 (red) while 






Figure 3 NADPH oxidation (grey) and product formation rates (blue-lined) of the optimal 
combination of the PFC decoy molecules with CYP102A1 WT and its variants for cyclopentane, 
cyclohexane, cyclooctane and cyclodecane hydroxylation. NADPH oxidation and product formation 












Figure 5 NADPH oxidation (grey) and product formation rates (blue-lined) of turnovers of 
cyclopentane and cyclohexane with WT, RP and KT2 variants in combination with the second 
generation of decoy molecules. NADPH oxidation rate and product formation rate are reported as 
mean (n  3) and given in nmol(nmol-CYP)–1min–1 (full data provided in Table S2). 
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